From Nasdaq: 2025-04-15 08:57:00

During uncertain times, investors turn to the consumer staples sector for stability and comfort. Brands in this sector, like Edgewell and Kenvue, offer familiar products that consumers trust. Edgewell, known for razors and skincare, reported weak Q1 2025 earnings, while Kenvue, behind Tylenol and Neutrogena, faced FX challenges in Q4 2024.

Edgewell’s revenue is heavily impacted by currency fluctuations, but a weaker dollar could boost international sales. Meanwhile, Kenvue’s earnings were affected by a strong U.S. dollar, but a 7% drop could turn headwinds into tailwinds. Both companies offer dividend yields, with potential for growth due to currency shifts.

Kenvue, a powerhouse in healthcare and beauty, faces challenges from a strong dollar and softer demand. However, with a drop in the dollar, the company could see improvements. Activist investors are eyeing Kenvue, potentially leading to a breakup or acquisition, offering additional catalysts for growth beyond currency changes and organic sales. 1. The stock market experienced a sharp decline today, with the S&P 500 dropping 2.5% and the Dow Jones Industrial Average falling 600 points. Investors are concerned about rising inflation rates and potential interest rate hikes by the Federal Reserve.

2. The latest job report shows that the unemployment rate has dropped to 4.2%, the lowest it has been since the start of the pandemic. However, job growth has slowed, with only 210,000 new jobs added in the past month, below economists’ expectations.

3. In international news, tensions between Russia and Ukraine continue to escalate, with reports of increased military activity on both sides. The United States and European Union have expressed concern over the situation and are calling for a peaceful resolution to the conflict.

4. The United Nations released a report stating that the global temperature has risen by 1.1 degrees Celsius since pre-industrial times. This surpasses the threshold set by the Paris Agreement and highlights the urgent need for countries to take action to combat climate change.

5. In health news, a new study found that the Pfizer-BioNTech COVID-19 vaccine is highly effective in preventing severe illness and hospitalization from the Omicron variant. The study showed an 80% reduction in hospitalizations among vaccinated individuals compared to those who were unvaccinated.



Read more at Nasdaq:: 2 Under-the-Radar Consumer Staples Stocks With Big Dividends